The global amyotrophic lateral sclerosis (ALS) therapeutics market is expected to expand significantly over the next decade, growing from USD 812 million in 2024 to USD 1,964 million by 2035, according to market analysis. This expansion represents a compound annual growth rate (CAGR) of 11.5% and reflects substantial momentum in the treatment landscape for the neurodegenerative disease.
Multiple factors are driving this market growth, including accelerating innovation in genetic therapy approaches and gene-silencing technologies that target disease mechanisms at a molecular level. Concurrently, advances in diagnostic capabilities and heightened disease awareness among healthcare providers and patients are expanding the addressable patient population and improving early detection rates.
Leading pharmaceutical companies including Biogen, Ionis Pharmaceuticals, and Amylyx Pharmaceuticals are among the key players actively developing disease-modifying treatments. These efforts represent a shift toward more targeted therapeutic options that extend beyond symptomatic management, positioning the ALS therapeutics sector for continued growth driven by clinical innovation and unmet patient needs.